Williams C J, Hopkins B A
Pfizer Animal Health, Third Avenue, New York, NY 10017, USA.
Poult Sci. 2011 Jan;90(1):223-6. doi: 10.3382/ps.2010-00759.
The location of injection and vaccine deposition in ovo is known to be critical to the efficacy of Marek's disease (MD) vaccine protection against MD viral challenge. Vaccine deposition into the amniotic sac or a s.c. or i.m. site of the embryo is required for MD vaccine efficacy. Vaccine deposition into the air cell or allantoic fluid results in chicks that are not adequately protected against subsequent MD viral challenge. A study was conducted in 2 commercial broiler hatcheries to evaluate the ability of 2 in ovo injection systems, the Embrex Inovoject system (Pfizer Poultry Health, Research Triangle Park, NC) and the Intelliject system (Avitech, Salisbury, MD; distributed by Merial Ltd., Gainesville, GA) to deliver a vaccine approved for use in ovo accurately and properly. A standard MD vaccine diluent mixed with a protein-staining dye was delivered through each machine to simulate in ovo vaccination. The location of the dye within the egg determined whether the vaccine was delivered correctly. Each egg was also evaluated for normal embryo development (normal eggs). Correct vaccine delivery included eggs in which the vaccine was injected into the amniotic sac or into s.c. or i.m. regions of the embryo. Incorrect vaccine delivery was defined as delivery into the air cell; allantoic sac; any combinations including air cell or allantois; the abdominal, cranial, orbital, or thoracic cavities of the embryo; or no vaccine delivery at all. In hatchery 1 (Chick Master, Newton, MS) 1,171 normal eggs were processed through the Inovoject system and 1,138 eggs were processed by the Intelliject system. The Inovoject system correctly vaccinated 94.62% of the normal eggs as compared with 61.16% delivery accuracy of normal eggs with the Intelliject system. In hatchery 2 (Jamesway Super J, Magee, MS) 926 normal eggs were processed by the Inovoject system and 910 normal eggs were processed by the Intelliject system. The Inovoject system correctly vaccinated 91.04% of the normal eggs, whereas the Intelliject system correctly vaccinated 71.98% of the normal eggs. The results of this study clearly demonstrate that the Inovoject system accurately delivered in ovo vaccine at a significantly higher rate than the Intelliject system.
已知在蛋内进行疫苗注射的位置以及疫苗的沉积情况对于马立克氏病(MD)疫苗抵御MD病毒攻击的效果至关重要。MD疫苗要发挥效力,需将疫苗沉积到羊膜囊或胚胎的皮下或肌肉部位。若将疫苗沉积到气室或尿囊液中,孵化出的雏鸡在后续面对MD病毒攻击时将无法得到充分保护。在两家商业肉鸡孵化场开展了一项研究,以评估两种蛋内注射系统,即Embrex Inovoject系统(辉瑞家禽保健公司,北卡罗来纳州三角研究园)和Intelliject系统(Avitech公司,马里兰州索尔兹伯里;由梅里亚有限公司在佐治亚州盖恩斯维尔经销)准确、恰当地输送经批准可用于蛋内注射疫苗的能力。将一种与蛋白质染色染料混合的标准MD疫苗稀释液通过每台机器输送,以模拟蛋内接种疫苗的过程。蛋内染料的位置决定了疫苗是否正确输送。还对每个鸡蛋的胚胎发育是否正常(正常鸡蛋)进行了评估。正确的疫苗输送包括疫苗被注射到羊膜囊或胚胎的皮下或肌肉区域的鸡蛋。不正确的疫苗输送定义为注射到气室;尿囊;包括气室或尿囊的任何组合;胚胎的腹腔、颅腔、眼眶或胸腔;或根本未进行疫苗输送。在孵化场1(密西西比州牛顿市的Chick Master),1171枚正常鸡蛋通过Inovoject系统处理,1138枚鸡蛋通过Intelliject系统处理。Inovoject系统正确接种了94.62%的正常鸡蛋,而Intelliject系统对正常鸡蛋接种的准确率为61.16%。在孵化场2(密西西比州马吉市的Jamesway Super J),926枚正常鸡蛋通过Inovoject系统处理,910枚正常鸡蛋通过Intelliject系统处理。Inovoject系统正确接种了91.04%的正常鸡蛋,而Intelliject系统正确接种了71.98%的正常鸡蛋。这项研究的结果清楚地表明,Inovoject系统以显著高于Intelliject系统的速率准确输送蛋内疫苗。